Survival following Hodgkin lymphoma (HL) has improved significantly over the past decades because of the development of more effective radiotherapy (RT) and chemotherapy (CT) regimens ([@bib6]). The current 10-year survival rates exceed 80%, leading to increasing numbers of HL survivors. Unfortunately, improved survival has been accompanied by late adverse events related to treatment ([@bib17]; [@bib37]; [@bib11]; [@bib25]; [@bib20]; [@bib1]; [@bib18]; [@bib32]; [@bib23]; [@bib14]; [@bib33]; [@bib29]; [@bib38]), of which subsequent malignant neoplasms (SMNs) and cardiovascular diseases (CVDs) contribute most to excess morbidity and mortality ([@bib24]; [@bib2]).

Several studies reported that HL survivors have an increased incidence of SMN and CVD compared with the general population ([@bib25]; [@bib1]; [@bib18]; [@bib14]; [@bib33]; [@bib29]; [@bib38]). Moreover, recent studies suggest that these increased risks persist even more than 40 years after initial treatment for HL ([@bib29]; [@bib38]). As HL often occurs at relatively young ages, these highly increased risks of late adverse events may pose a large burden on survivors. Until now, research has focussed on separate risk estimates for SMN and CVD and we are not aware of studies examining SMN and CVD as a combined end point in HL survivors. However, a proportion of HL survivors may develop both SMN and CVD -- or even multiple SMNs or CVDs -- leading to increased morbidity and mortality among these survivors.

This study examines the combined risk of SMNs and CVDs in a large cohort of HL survivors with long-term and complete follow-up, providing more insight into the total burden of morbidity from these late effects.

Patients and methods
====================

Data collection procedures
--------------------------

We performed a cohort study in 2979 patients treated for HL in five university hospitals or cancer centres (The Netherlands Cancer Institute Amsterdam, the Erasmus MC Cancer Institute Rotterdam, Leiden University Medical Centre, Radboud University Medical Centre Nijmegen, and University Medical Centre Utrecht) in The Netherlands. The selection of patients has been described in detail previously ([@bib36], [@bib37]; [@bib2], [@bib1]; [@bib9]; [@bib35]). In brief, patients were below age 51 years at HL diagnosis, treated between 1965 and 2000, and had survived ⩾5 years after HL diagnosis.

From the medical records, the following information was collected: date of HL diagnosis; treatment modalities of primary and salvage treatment (i.e., radiation fields, chemotherapeutic agents, and number of cycles); dates of CVD diagnoses; dates of diagnoses of SMNs; and date of most recent medical information or date of death. Information on subsequent malignancies since 1989 was obtained by record linkage with the Netherlands Cancer Registry ([@bib29]). Vital status and dates of death were obtained through linkage with the Dutch Central Bureau for Genealogy. Additionally, follow-up data on CVDs and SMNs were retrieved by contacting the patients' general practitioners and cardiologists ([@bib38]). Data on both SMN and CVD were complete until at least 31 December 2013. This study was exempt from institutional review board approval according to Dutch law because existing data from medical files were used.

The following cardiovascular events were included: coronary heart disease (CHD), including myocardial infarction (MI) and angina pectoris (AP); valvular heart disease (VHD); and heart failure (HF), including congestive heart failure (CHF) and cardiomyopathy (CMP). All events were defined and graded according to a slightly adapted version of the Common Terminology Criteria of Adverse Events, version 4.0 (69% graded cardiovascular events). VHD with grade 1 (*n*=83) was excluded from the analyses, because these events do not pose a large burden on patients. Additionally, we excluded VHD with unknown grade (*n*=110) as we assumed, based on a previous case--control study, that many of such events were also grade 1 ([@bib8]). Consequently, the cardiovascular disease rates presented in this paper will be slightly conservative. To prioritise CVD events when multiple CVDs were diagnosed on the same date, decision rules were developed with a cardiologist (WEMK; [Supplementary Methods I](#sup1){ref-type="supplementary-material"}). In short, CHD was prioritised over VHD and HF, and HF over VHD. Only one VHD was considered in the analysis; we included multiple MIs if the interval between two MIs was ⩾3 months. The AP following a MI diagnosis was included when the interval between the two events was ⩾6 months. We included all invasive SMNs in the analyses, except basal cell carcinomas of skin. Subsequent malignancies occurring in paired organs were included if the latter was not considered to be a recurrence of the previous malignancy. Both incident and fatal SMNs and CVDs were included.

Treatment
---------

Over time, a wide variety of treatment regimens was used, although most patients were treated according to the European Organisation for Research and Treatment of Cancer Lymphoma Group protocols ([@bib7]; [@bib28]; [@bib12]). Earlier reports have described frequently used treatments and changes over time ([@bib1]; [@bib35]). Patients treated with radiotherapy alone usually received 40 Gray (Gy) in fractions of 1.5--2.0 Gy, whereas patients who also received chemotherapy received 30--36 Gy in similar fractions. Individual shielding was used to limit normal tissue exposure as much as possible. Mantle field irradiation (including mediastinal, axillary, and neck nodes) was the most common supradiaphragmatic radiation field applied from the early 1970s to the late 1980s. Since then, an increasing number of patients received more limited radiation fields (involved field radiation).

From the 1960s to the 1980s, chemotherapy for HL mainly consisted of MOPP (mechloretamine, vincristine, procarbazine, prednisone). In the 1980s, anthracycline-containing regimens, such as MOPP/ABV (mechloretamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vinblastine) and ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), were introduced as a part of primary treatment. More detailed information on main radiotherapy fields and anthracyclines stratified by treatment period are presented in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

Statistical analysis
--------------------

Patients were categorised into treatment groups based on radiation fields and chemotherapy regimens administered in both primary and salvage treatment ([Supplementary Methods II](#sup1){ref-type="supplementary-material"}). To assess the risk of SMN and CVD, the following outcome measures were used: diagnosis of either SMN or CVD as first event, and diagnosis of both SMN and CVD. When examining the risk of developing SMN or CVD, time at risk began 5 years after the start of initial HL treatment and ended at date of diagnosis of either SMN or CVD, date of most recent medical information, date of migration, or date of death, whichever came first. When analysing the development of both SMN and CVD as the outcome, time at risk ended at date of diagnosis of the last of the two events. Patients diagnosed with a SMN or CVD before or within 5 years after HL diagnosis (*n*=9 and *n*=62, respectively) were excluded ([Supplementary Methods III](#sup1){ref-type="supplementary-material"}).

The burden from SMN and CVD events in our cohort was assessed in three different ways. First, the cumulative incidences (CIs) of either SMN or CVD as first event, and of development of both SMN and CVD, was estimated in the presence of death as competing risk. Second, the cumulative incidence of developing at least one, two, three, or four events was estimated. Third, we used the method of mean cumulative count (MCC) to take all SMN and CVD events in our cohort into account ([@bib10]). The MCC reflects the average number of events of interest per individual in a population within a given period of time, taking both first and subsequent events into account. Patients who experience an event (or multiple events) remain in the risk set until they either experience a competing risk (death) or are censored. In this analysis, all SMN and CVD events were taken into account.

We performed multivariable Cox regression analyses to quantify the effects of HL treatments on the risk of SMN or CVD as first event and the risk of both SMN and CVD. The proportional hazards assumption was assessed using residual-based methods. An interaction term of age at HL treatment and time was included in the Cox regression models, because hazards were non-proportional by age. Additionally, models were adjusted for sex. Interaction between radiotherapy and chemotherapy was assessed using standard methods. The *P-*values of \<0.05 were considered statistically significant. Analyses were performed using Stata statistical software, version 13 (StataCorp, College Station, TX, USA).

Results
=======

In total, 2908 5-year HL survivors were included in the analyses. Median age at HL treatment was 27.3 years ([Table 1](#tbl1){ref-type="table"}). In the majority of patients, treatment for HL consisted of radiotherapy alone (27.1%), or in combination with chemotherapy (65.9%). Among patients treated with radiotherapy, 25.7% received subtotal nodal irradiation, 24.5% received mantle field irradiation, and 16.2% received other supradiaphragmatic radiation fields. After a median follow-up of 21.8 years, we identified 888 SMNs and 1153 CVDs in 1247 patients; 240 patients developed both SMN and CVD. Median age at first event was 49.8 years (interquartile range (IQR)=42.4--56.5) and patients with both an SMN and CVD had a median age of 56.9 years (IQR=49.4--63.8) at diagnosis of the second event. Of all patients who developed a SMN or CVD, 270 patients developed a subsequent event and 160 patients even developed two subsequent events.

[Figure 1](#fig1){ref-type="fig"} illustrates the pattern of subsequent second and third SMN and CVD events following either CHD, gastrointestinal, or breast cancer as a first event and the time interval between these events. A total of 357 patients developed CHD after HL treatment, with a median time between HL and CHD diagnosis of 18.3 years (IQR=13.2--24.0). As most patients survive a CHD event, many subsequent events were observed in these patients. Following CHD diagnosis, 51 patients developed VHD and 45 patients HF. After a median follow-up of 20.1 years (IQR=15.3--26.7), a total of 118 patients developed breast cancer, of whom 14 developed another breast cancer (median interval 3.0 years; IQR=0.9--7.7) and 12 developed CHD (median interval 5.8 years; IQR=3.1--9.2). Few subsequent events were observed following cancers with a relatively poor prognosis, for example, gastrointestinal and lung cancer ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}).

Overall burden
--------------

At 40 years after HL, the cumulative incidence of developing either SMN or CVD was 67.8% (95% CI=65.1--70.4); the cumulative incidence of developing both SMN and CVD was 17.2% (95% CI=15.0--19.6) ([Figure 2A](#fig2){ref-type="fig"}). Several patients developed either multiple SMNs or multiple CVDs, but not a SMN and a CVD ([Figure 2B](#fig2){ref-type="fig"}). At 40 years, the cumulative incidence for at least two events was 32.3% (95% CI=29.5--35.1), whereas the cumulative incidences for at least three or four events were 12.5% (95% CI=10.6--14.6) and 2.6% (95% CI=1.7--3.8), respectively. The MCC analysis, which takes all subsequent SMN and CVD events into account, showed that by 40 years after treatment an average of 122 events had occurred per 100 survivors (MCC=1.2) ([Figure 2C](#fig2){ref-type="fig"}). Patients who had relapsed were not at higher risk to develop SMN or CVD compared with patients who did not relapse ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}).

Patients treated at ages ⩾35 years had a higher cumulative incidence of SMN or CVD than patients treated at younger ages ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). The 30-year cumulative incidence of SMN or CVD for patients treated at ages ⩾35 years was 62.5% (95% CI=58.1--66.6), whereas the 30-year cumulative incidence for patients treated at ages 25--34 years was 52.4% (95% CI=48.3--56.4), and for patients ⩽25 years at treatment 43.8% (95% CI=40.2--47.4). The difference between these age groups was even more pronounced when we considered the MCC analysis. At 30 years since treatment, the mean number of events per 100 patients treated at ages ⩾35 years was twice that of patients ⩽25 years at treatment (50 *vs* 100 events). No clear differences were observed in the cumulative burden in different periods of diagnosis ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}).

Risk of subsequent events after a first SMN or CVD diagnosis
------------------------------------------------------------

We assessed whether the risk of developing SMN or CVD as second event after HL -- in this case as separate outcomes -- differed between HL patients who first developed a solid SMN and those who first developed a CVD ([Figure 3](#fig3){ref-type="fig"}). The 15-year cumulative incidence of SMN was nearly identical after a solid SMN and after a CVD as first event (15.8%, 95% CI=12.2--19.7, and 15.0%, 95% CI=11.8--18.6, respectively). However, the 15-year cumulative incidence for CVD as second event was much higher following a CVD as first event after HL (46.1%, 95% CI=41.3--50.7) than following a solid SMN as first event after HL (15.2%, 95% CI=11.7--19.0). This high cumulative incidence of a CVD following a previous CVD was most pronounced after CHD or VHD as first event after HL ([Supplementary Figure 4](#sup1){ref-type="supplementary-material"}).

Treatment-specific risks
------------------------

[Table 2](#tbl2){ref-type="table"} shows the results of multivariable Cox regression analyses for the risk of developing either SMN or CVD as a first event and for developing both SMN and CVD. Compared with patients receiving no or limited radiation fields, an increased risk of developing either SMN or CVD was observed for all radiotherapy fields including a supradiaphragmatic component. Mantle field radiotherapy was associated with a 2.6-fold increased risk to develop either SMN or CVD (95% CI=2.1--3.4) and the risk was slightly higher in patients receiving more extensive radiotherapy fields including subtotal nodal and total nodal radiotherapy (HR=3.0, 95% CI=2.3--3.8, and HR=2.7, 95% CI=2.0--3.7). Anthracycline-containing chemotherapy was associated with a 1.3-fold increased risk to develop either SMN or CVD (95% CI=1.1--1.5). No increased SMN or CVD risk was observed for high-dose procarbazine (i.e., \>4.2 g m^−2^) compared with low-dose procarbazine, other non-alkylating chemotherapy, or no chemotherapy. Separate models with SMN as first event or CVD as first event are presented in the [Supplementary Table 2](#sup1){ref-type="supplementary-material"}.

The risk of developing both SMN and CVD increased with larger radiotherapy volumes. An incomplete mantle field was associated with a 4.1-fold increased risk (95% CI=1.7--9.7), whereas (sub)total nodal radiotherapy increased the risk of developing both SMN and the CVD more than 6-fold (HR=6.4, 95% CI=2.9--14.0). Chemotherapy was not associated with risk of developing both SMN and CVD.

Smoking was independently associated with increased risk of developing SMN or CVD (HR=1.4, 95% CI=1.2--1.6) and with development of both SMN and CVD (HR=1.6, 95% CI=1.2--2.1). We observed no interaction between radiotherapy and chemotherapy.

The cumulative burden of developing SMN or CVD was assessed for several radiotherapy regimens stratified for type of chemotherapy ([Figure 4](#fig4){ref-type="fig"}). Among patients who received no and no alkylating chemotherapy (except low-dose procarbazine), the cumulative incidence at 25 years was 15.5% (95% CI=6.8--27.4) for no or limited radiotherapy. In contrast, the 25-year cumulative incidence of SMN or CVD for patients who received mantle field radiotherapy was 38.3% (95% CI=33.0--43.7) and for subtotal nodal radiotherapy 47.9% (95% CI=42.9--52.7). The MCC analysis showed the same pattern. Comparable cumulative incidences were observed for the different radiotherapy regimens among patients receiving high-dose procarbazine ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"}). However, among patients who received anthracyclines, slightly higher risks of SMN or CVD were observed for the different radiotherapy regimens, compared with patients receiving no chemotherapy, low-dose procarbazine, high-dose procarbazine, or non-alkylating chemotherapy. Anthracyclines in combination with mantle field radiotherapy resulted in a 25-year cumulative incidence of 51.4% (95% CI=42.2--59.8) and in combination with subtotal nodal radiotherapy in a cumulative incidence of 49.0% (95% CI=39.5--57.8).

Discussion
==========

With this study, we are the first to describe the combined burden from SMNs and CVDs in adolescent and young adult patients treated for HL. At 40 years of follow-up, the cumulative incidence of either SMN or CVD was 68% and the cumulative incidence of developing both a SMN and a CVD was 17%. Taking all SMN and CVD events into account, every survivor had developed, on average, 1.2 events at 40 years of follow-up. The HL patients who developed a solid malignancy had similar 15-year risks to develop another subsequent malignancy or CVD (15%), whereas patients who developed a CVD after HL had a higher 15-year risk to develop another CVD compared with a subsequent malignancy (46 *vs* 15%). Both larger radiotherapy volumes and anthracycline-containing chemotherapy increased the risk of developing either SMN or CVD, whereas only supradiaphragmatic radiotherapy was associated with an increased risk of developing both SMN and CVD.

Several studies have examined the burden of disease in childhood cancer survivors ([@bib26]; [@bib15]; [@bib19]). Although these studies also observed a high disease burden among children treated for cancer, these findings are not directly comparable to the findings in our current study. In the childhood cancer survivor reports, all chronic conditions were taken into account, whereas we restricted our analyses to SMN and CVD as the most severe complications of HL treatment. A major difference relates to the assessment of adverse events. We obtained data on the *incidence* of SMNs and CVDs from hospital medical records, questionnaires to general practitioners, and linkage with the NCR. These data were prospectively collected for all patients during the course of follow-up. In the childhood cancer survivor reports, where chronic conditions were assessed through patient questionnaires or medical assessments, *prevalence* of disease was assessed in survivors who were still alive and responded to questionnaires or attended the clinic.

Unfortunately, this study could not compare the combined risk of SMN and CVD to that in the general population. No reference data are available that combine cancer and CVD rates. However, we know from previous studies assessing the risk of either SMN or CVD risk following HL that both these risks are increased compared with rates in the general population ([@bib25]; [@bib1]; [@bib18]; [@bib14]; [@bib33]; [@bib29]; [@bib38]). From earlier studies we also know that HL patients have an increased risk to develop multiple SMNs or multiple CVDs related to treatment ([@bib4]; [@bib35]; [@bib5]). With respect to multiple SMN risk, it was found that HL patients who developed SMN remained at an increased risk to develop subsequent malignancies ([@bib4]; [@bib35]). A recent paper showed that survivors of childhood HL are at increased risk to develop multiple CVDs, with five times more events at the same point during follow-up among HL survivors compared with community controls ([@bib5]). These studies suggest that the burden of SMN and CVD is high among HL survivors; however, the combined risk of SMN and CVD was not previously described.

There are several statistical measures to assess disease burden in cohort studies. In this study, we used two different statistical methods. First, we calculated the cumulative incidence to develop SMN or CVD, and both SMN and CVD. Using cumulative incidence, patients are censored at the time of the first event of interest. Here, patients who experience a competing-risk event and patients experiencing the event of interest are removed from the risk set. We also determined the risk of developing one, two, three, or four events. Second, we used the method of mean cumulative count that provides the ability to take multiple, or recurring, events into account ([@bib10]). Using MCC, patients can experience the event of interest multiple times and still remain at risk for subsequent events of interest. Here, we also took into account multiple CVDs according to our decision rules that in our opinion is important from a patient's perspective, as these events are probably associated with multiple visits to doctors, various treatments, and hospital admissions. The cumulative incidence and MCC reflect the burden of disease in a different way and we believe that both methods combined adequately reflect the total burden of SMN and CVD in our cohort.

We used the CTCAE to exclude VHD with grade 1 or unknown grade, because we wanted to restrict our analyses to more severe events. The CTCAE is frequently used to assess the severity of late complications of treatment. Especially for CVDs, CTCAE grading was useful; in our cohort, cardiovascular events with grade 2 mainly concerned angina pectoris and VHD. We did not take grade into account in our analyses, as for subsequent malignancies the CTCAE grading system is less informative as all SMNs are coded equally (i.e., grade 4), irrespective of topography, morphology, and stage. For example, stage I breast cancer has the same grade as stage III lung cancer. For future studies on burden from SMNs, we think a more precise grading system, that is, taking prognosis of subsequent malignancies into account, is needed.

The purpose of this study was to assess the total burden of morbidity from both SMN and CVD. When examining treatment-related risks on developing SMN and CVD as combined outcome, this means that if a certain treatment has a differential effect on the two outcomes, these effects may balance out in the analyses. For example, high-dose procabarzine increases the risk of gastrointestinal cancer ([@bib22]; [@bib29]), whereas it decreases breast cancer risk ([@bib34]; [@bib31]; [@bib29]). This may explain why we did not observe an increased risk of SMN and CVD after high-dose procarbazine.

Patients in our cohort were treated for HL between 1965 and 2000 according to treatment regimens commonly used in the Western world. Inherent to late effects research, many of those regimens are no longer commonly used. Over the past decades, effective chemotherapy was introduced that enabled reduction of radiotherapy volumes and dose, while maintaining high survival rates ([@bib6]; [@bib30]). In the current study, the highest risk of developing either SMN or CVD, or both SMN and CVD, was associated with large radiotherapy volumes that included a supradiaphragmatic field. Although the largest burden was posed by radiotherapy, anthracyclines were also associated with an increased SMN or CVD risk as combined outcome. We found no clear differences in the risk to develop either SMN or CVD by period of treatment. However, we expect that patients treated from 2000 onwards will experience a lower disease burden because of risk-adapted HL treatment ([@bib13]; [@bib3]), further reduction of radiotherapy volumes ([@bib16]), and introduction of modern radiation techniques ([@bib21]; [@bib27]).

In conclusion, HL patients treated between 1965 and 2000 experience a high disease burden from both SMN and CVD after HL treatment. Treating physicians should be aware that survivors diagnosed with a SMN or CVD also have a high risk of subsequent events, implying that expertise in cardio-oncology is crucial in the follow-up care of HL survivors.
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###### 

Click here for additional data file.

![**Flowchart of subsequent malignancies and cardiovascular diseases in Hodgkin lymphoma survivors.** Subsequent events are shown when the first event is coronary heart disease (CHD; including both myocardial infarction and angina pectoris, with 54% myocardial infarction among CHD as first event), gastrointestinal cancer (GI; including all malignant neoplasms of digestive organs corresponding with ICD-10 codes C15--C26) and breast cancer (ICD-10 code C50). Subsequent events included valvular heart disease (VHD), heart failure (HF), lung cancer (ICD-10 codes C33--C34), haematologic cancer (ICD-10 codes C82--C96), and other solid malignancies. Median time between subsequent events expressed in years. CVD=cardiovascular disease; SMN=subsequent malignant neoplasm](bjc2017476f1){#fig1}

![**Different measures of the cumulative burden of subsequent malignancies and cardiovascular diseases in Hodgkin lymphoma survivors.** (**A**) Overall cumulative incidence for developing subsequent malignancy (SMN) or cardiovascular disease (CVD) as first event and for developing both subsequent malignancy and cardiovascular disease. (**B**) Cumulative incidence for at least one, two, or three subsequent malignancies or cardiovascular diseases (irrespective of whether they concerned an SMN or CVD). (**C**) Overall mean cumulative count for all subsequent malignancies and cardiovascular diseases.](bjc2017476f2){#fig2}

![**Cumulative incidence of subsequent malignancy and cardiovascular disease among survivors who developed a first event (solid malignancy or CVD) after Hodgkin lymphoma.** (**A**) Cumulative incidence for developing subsequent malignancy (SMN) or cardiovascular disease (CVD) among survivors who developed a solid malignancy as first event. (**B**) Cumulative incidence for developing SMN or CVD among survivors who developed cardiovascular disease as first event.](bjc2017476f3){#fig3}

![**Different measures of the cumulative burden of subsequent malignancies and cardiovascular disease by treatment modality.** For patients receiving no anthracyclines and no alkylating chemotherapy (except low-dose procarbazine), (**A**) the cumulative incidence of developing subsequent malignancy or cardiovascular disease as first event and (**B**) the mean cumulative count for all subsequent malignancies and cardiovascular diseases by radiotherapy field are shown. For patients receiving anthracycline-containing chemotherapy, (**C**) the cumulative incidence of developing subsequent malignancy or cardiovascular disease as first event and (**D**) the mean cumulative count for all subsequent malignancies and cardiovascular diseases by radiotherapy field are shown. Incomplete mantle field radiotherapy is only shown in the graphs for patients receiving anthracycline-containing chemotherapy because in the anthracycline era smaller radiotherapy fields were introduced.](bjc2017476f4){#fig4}

###### Characteristics of all Hodgkin lymphoma patients and patients with SMN and/or CVD

                                                        **Total cohort (*****n*****=2908)**   **Patients with SMN or CVD**[a](#t1-fn2){ref-type="fn"} (***n*****=1247)**   **Patients with SMN and CVD (*****n*****=240)**                      
  ---------------------------------------------------- ------------------------------------- ---------------------------------------------------------------------------- ------------------------------------------------- ------------ ------ ------------
  **Sex**                                                                                                                                                                                                                                       
  Male                                                                 1636                                                      56.3                                                            684                            54.9      112       46.7
  Female                                                               1272                                                      43.7                                                            563                            45.2      128       53.3
  **Age at first HL treatment (years)**                                                                                                                                                                                                         
  Median (IQR)                                                         27.3                                                   21.6--35.3                                                        28.9                         22.3--37.5   30.4   23.3--37.4
  \<25                                                                 1165                                                      40.1                                                            445                            35.7       79       32.9
  25--34                                                                987                                                      33.9                                                            411                            33.0       79       32.9
  35--50                                                                756                                                      26.0                                                            391                            31.4       82       34.2
  **Treatment period**                                                                                                                                                                                                                          
  1965--1976                                                            786                                                      27.0                                                            493                            39.5      118       49.2
  1977--1988                                                           1077                                                      37.0                                                            530                            42.5      103       42.9
  1989--2000                                                           1045                                                      35.9                                                            224                            18.0       19       7.9
  **Follow-up time (years)**                                                                                                                                                                                                                    
  Median (IQR)                                                         21.8                                                   15.9--29.4                                                        25.7                         18.8--32.9   29.9   24.3--37.3
  5--9                                                                  280                                                      9.6                                                             72                             5.8        4        1.7
  10--19                                                                985                                                      33.9                                                            292                            23.4       29       12.1
  20--29                                                                957                                                      32.9                                                            457                            36.7       90       37.5
  30--39                                                                547                                                      18.8                                                            327                            26.2       79       32.9
  ⩾40                                                                   139                                                      4.8                                                             99                             7.9        38       15.8
  **Treatment category**                                                                                                                                                                                                                        
  Radiotherapy only                                                     789                                                      27.1                                                            434                            34.8      105       43.8
  Chemotherapy only                                                     202                                                      7.0                                                             51                             4.1        4        1.7
  Radiotherapy and chemotherapy                                        1917                                                      65.9                                                            762                            61.1      131       54.6
  **Relapse**                                                                                                                                                                                                                                   
  Yes                                                                   835                                                      28.7                                                            377                            30.2       69       28.7
  No                                                                   2073                                                      71.3                                                            870                            69.8      171       71.3
  **Radiotherapy fields[b](#t1-fn3){ref-type="fn"}**                                                                                                                                                                                            
  Limited radiation fields                                              146                                                      5.0                                                             31                             2.5        3        1.3
  Inverted-Y                                                            133                                                      4.6                                                             43                             3.5        6        2.5
  Incomplete mantle field                                               470                                                      16.2                                                            131                            10.5       22       9.2
  Mantle field                                                          713                                                      24.5                                                            383                            30.7       83       34.6
  Incomplete subtotal nodal                                             237                                                      8.2                                                             92                             7.4        15       6.3
  Subtotal nodal                                                        747                                                      25.7                                                            409                            32.8       87       36.3
  Total nodal                                                           203                                                      7.0                                                             96                             7.7        18       7.5
  Fields unknown                                                        57                                                       2.0                                                             11                             0.9        2        0.8
  No radiotherapy                                                       202                                                      7.0                                                             51                             4.1        4        1.7
  **Chemotherapy**                                                                                                                                                                                                                              
  No anthracyclines                                                     961                                                      33.1                                                            487                            39.1       99       41.3
  Anthracyclines                                                       1158                                                      39.8                                                            326                            26.1       36       15.0
   Median dose (IQR), mg m^−2^                                          210                                                    150--280                                                          210                          210--300    280     210--300
  No procarbazine                                                       581                                                      20.0                                                            249                            20.0       50       20.8
  ⩽4.2 g m^−2^ procarbazine dose                                        612                                                      21.1                                                            188                            15.1       20       8.3
  \>4.2 g m^−2^ procarbazine dose                                       926                                                      31.8                                                            376                            30.2       65       27.1
  No chemotherapy                                                       789                                                      27.1                                                            434                            34.8      105       43.8

Abbreviations: CVD=cardiovascular disease; HL=Hodgkin\'s lymphoma; IQR=interquartile range; SMN=subsequent malignant neoplasm.

Also includes patients with a subsequent malignancy and cardiovascular disease. Patients may have been diagnosed with multiple subsequent malignancies and/or cardiovascular diseases.

Limited radiation fields included small radiation volumes including supra- or infraclavicular field, inguinal field, or iliac field only. Incomplete mantle field was defined as irradiation above the diaphragm including the mediastinum or the axilla. Incomplete subtotal nodal included the combination of incomplete mantle field with radiation fields below the diaphragm or the combination of mantle field with an inguinal and/or iliac field.

###### Treatment-related risk factors for developing either subsequent malignancy and cardiovascular disease (as combined event) and for developing both subsequent malignancy and cardiovascular disease

                                                         **SMN or CVD (*****n*****=2851)**   **SMN and CVD (*****n*****=2851)**             
  ----------------------------------------------------- ----------------------------------- ------------------------------------ ---------- -----------------
  **Radiotherapy[a](#t2-fn3){ref-type="fn"}**                                                                                               
  No or limited radiation exposure                                    82/348                             1.0 (Ref.)                7/348       1.0 (Ref.)
  Inverted-Y                                                          43/133                           1.2 (0.8--1.7)              6/133     1.9 (0.6--5.6)
  Incomplete mantle field                                             131/470                          1.9 (1.4--2.5)              22/470    4.1 (1.7--9.7)
  Mantle field                                                        383/713                          2.6 (2.1--3.4)              83/713    5.9 (2.7--13.0)
  Incomplete subtotal nodal                                           92/237                           2.6 (2.0--3.6)              15/237    6.1 (2.5--15.0)
  Subtotal nodal                                                      409/747                          3.0 (2.3--3.8)             105/950    6.4 (2.9--14.0)
  Total nodal                                                         96/203                           2.7 (2.0--3.7)                                
  **Chemotherapy regimen[b](#t2-fn4){ref-type="fn"}**                                                                                       
  No chemotherapy/low-dose procarbazine/other                        651/1147                            1.0 (Ref.)               154/1147     1.0 (Ref.)
  Anthracyclines                                                     324/1129                          1.3 (1.1--1.5)             36/1129    1.1 (0.7--1.6)
  High-dose procarbazine                                              261/575                          0.9 (0.8--1.1)              48/575    1.0 (0.7--1.3)
  **Smoking**                                                                                                                               
  Never                                                              458/1266                            1.0 (Ref.)               80/1266      1.0 (Ref.)
  Ever                                                               741/1408                          1.4 (1.2--1.6)             156/1408   1.6 (1.2--2.1)
  Unknown                                                             37/177                           0.9 (0.6--1.2)              2/177     0.4 (0.1--1.8)

Abbreviations: CI=confidence interval; CVD=cardiovascular disease; HR=hazard ratio; *n/N*=number of events/number of patients in category; Ref.=reference; SMN=subsequent malignant neoplasm.

Model was adjusted for sex and age at Hodgkin lymphoma (HL) diagnosis, and including an interaction term of time and age at HL diagnosis.

Limited radiation fields were defined as supraclavicular field, infraclavicular field, cervical field, inguinal field, or iliac field only. Incomplete mantle field was defined as irradiation above the diaphragm including the mediastinum or the axilla. Incomplete subtotal nodal included the combination of incomplete mantle field with radiation fields below the diaphragm or the combination of mantle field with an inguinal and/or iliac field. To assess the risk of developing both subsequent malignancy and cardiovascular disease, radiotherapy categories subtotal nodal and total nodal were combined to increase power. Patients for whom the field of radiotherapy was unknown were omitted from the analysis.

Low-dose procarbazine was defined as ⩽4.2 g m^−2^ procabazine dose, corresponding to three cycles of a hybrid regimen of mechloretamine, vincristine, procarbazine, and prednisone (MOPP). Other chemotherapy included various non-alkylating (single) agents, including mainly vinblastine. Patients receiving anthracycline-containing chemotherapy were categorised in the anthracyclines group, irrespective of procarbazine dose. The high-dose procarbazine group excluded patients receiving anthracyclines and was defined as a procarbazine dose of \>4.2 g m^−2^ procarbazine, corresponding to more than three cycles of MOPP or more than six cycles of MOPP-ABV.
